Mechanism of Action
BPC-157 exerts its effects through multiple pathways that converge on tissue repair and cytoprotection.
Nitric Oxide Modulation
BPC-157 modulates nitric oxide (NO) synthesis, a key mediator of vascular tone and inflammation. It upregulates endothelial NO synthase (eNOS), promoting vasodilation and improved local blood flow to injured tissue. This pro-angiogenic effect is central to its accelerated healing properties.Growth Factor Upregulation
Research shows BPC-157 upregulates several growth factors critical to tissue repair, including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and early growth response protein 1 (EGR-1). Increased VEGF expression promotes neovascularization in ischemic or damaged tissue.[1]Tendon and Collagen Synthesis
BPC-157 stimulates tendon fibroblast migration and proliferation, and increases expression of the tendon growth factor receptor. It promotes collagen type I and III synthesis, which is critical for structural tendon and ligament repair. These effects have been consistently reproduced across multiple animal models of tendon transection and crush injury.[2]Gut-Brain Axis
BPC-157 interacts with the dopaminergic and serotonergic systems, modulating neurotransmitter balance. It demonstrates gastroprotective effects by preserving mucosal integrity, stimulating mucus production, and counteracting NSAID-induced and alcohol-induced gastric damage. Its interaction with the vagus nerve suggests systemic signaling beyond the gastrointestinal tract.[3]Research Overview
Tendon & Ligament Healing
Most StudiedBPC-157 consistently accelerates healing of transected, crushed, and otherwise damaged tendons in rodent models. Studies show complete transected Achilles tendons in BPC-157-treated animals recover functional load-bearing capacity significantly faster than controls. The peptide also accelerates healing of quadriceps, patellar, and rotator cuff models.[2]
Gut & Mucosal Protection
Strong EvidenceGastric and intestinal mucosal protection is the most consistently reproduced effect. BPC-157 prevents and heals ulcers induced by NSAIDs, ethanol, cysteamine, and stress. It also shows efficacy in models of inflammatory bowel disease (IBD), short bowel syndrome, and anastomotic healing after bowel surgery.[3]
Bone Healing
Moderate EvidenceSegmental bone defect models show accelerated bridging and callus formation in BPC-157 groups. The mechanism appears to involve upregulation of bone morphogenetic proteins (BMPs) and enhanced vascularization of the repair zone.[4]
Neurological Effects
EmergingBPC-157 has shown neuroprotective effects in models of traumatic brain injury, spinal cord injury, and peripheral nerve crush. It counteracts dopaminergic and serotonergic imbalances, with relevance to models of depression, Parkinson's disease, and addiction withdrawal.[5]
Calculate your BPC-157 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Tissue / tendon healing | 250–500 µg | Twice daily | Subcutaneous near injury site |
| Gut / mucosal protection | 250–500 µg | Once daily | Oral (capsule or solution) |
| Conservative start | 200 µg | Once daily | Subcutaneous |
| Systemic healing | 500 µg | Once daily | Subcutaneous (abdomen or near site) |
Morning dosing on an empty stomach is common for systemic protocols. For localized injury, injection near (not into) the injury site may improve local delivery. Oral administration shows bioavailability due to BPC-157's stability in gastric acid.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
BPC-157 demonstrates a strong safety profile in preclinical research with no reported LD50 (lethal dose) established in standard rodent models, suggesting very low acute toxicity.
Common observations: Mild injection site reactions (redness, temporary swelling) are the most frequently noted adverse effects. These are typically self-limiting.
Long-term data: Chronic administration studies in rodents spanning 3–6 months show no significant organ toxicity, histological abnormalities, or hematological changes at research doses.
Warnings: No FDA approval for human therapeutic use. Human clinical trial data is limited. Not recommended during pregnancy or breastfeeding. All human use is experimental and outside approved medical practice.
References
- [1]Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Curr Pharm Des. 2011;17(16):1612-32. PMID:21348480
- [2]Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-780. PMID:21071588
- [3]Sikiric P, et al. "Gastroprotective effect of body protection compound BPC-157 through protein- and cytoprotection-related mechanisms." J Physiol Pharmacol. 2009;60(7 Suppl):1-10. PMID:20103707
- [4]Duzel A, et al. "Stable gastric pentadecapeptide BPC 157 in the stress induced lesions in the nonglandular stomach. Sikiric 2001." J Physiol Paris. 2001;95(1-6):71-74. PMID:11595226
- [5]Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857-865. PMID:27498377
Community Reports
Inject at or near injury site when possible. For gut protocols, oral capsules (250-500 µg/cap) on empty stomach preferred. No food 30 min before or after oral dose.